Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.4 (
RNase H
)
2,751
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Two distinct class 1 and class 2 rat liver
IGF-I
mRNAs contain different 5' leader exons, 1 and 2. RNase protection, primer extension, RACE PCR and
ribonuclease H
mapping established the complete structure of the 5' end of class 1 and class 2
IGF-I
mRNAs. Two major transcription start sites in exon 1 yield class 1
IGF-I
mRNAs, including 345 or 245 bases of exon 1. Multiple, clustered transcription start sites in exon 2 yield class 2
IGF-I
mRNAs with 84-50 bases of exon 2. Cell-free translation of in vitro transcribed
IGF-I
mRNAs suggests that class 1 and class 2 mRNAs preferentially initiate translation at distinct AUG codons to result in
IGF-I
precursors with either 48 residue class 1 pre-peptides or 32 residue class 2 pre-peptides. Some translation initiation also occurs at a downstream AUG common to class 1 and 2 mRNAs to yield
IGF-I
precursors with a 22 residue pre-peptide. Inclusion of microsomal membranes in translations suggests that the three different pre-peptides each function as co-translationally cleaved signal peptides. However, treatment of processed precursors with endoglycosidase H indicates that co-translational processing of precursors with 22 and 32 residue pre-peptides leads to glycosylation of downstream
IGF-I
precursor sequences whereas co-translational processing of precursors with 48 residue pre-peptide is not associated with glycosylation.
...
PMID:Multiple transcription start sites in the rat insulin-like growth factor-I gene give rise to IGF-I mRNAs that encode different IGF-I precursors and are processed differently in vitro. 827 98